Roche has reported positive results from the final analysis of the phase III study CLL11 assessing Gazyva/Gazyvaro (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL).
The multi-centre, open-label, randomised three-arm investigated the safety and efficacy profile of Gazyva/Gazyvaro plus chlorambucil in comparison with MabThera/Rituxan plus chlorambucil or chlorambucil alone in nearly 800 people with previously untreated CLL and comorbidities.
Go deeper with GlobalData
The study’s primary endpoint is progression-free survival (PFS) and secondary endpoint included response rate, molecular remission rate, overall survival (OS), TTNT and safety profile.
Final results after a follow-up of nearly five years showed clinically meaningful improvements with Gazyva/Gazyvaro plus chlorambucil across multiple endpoints, including PFS and OS, when compared with MabThera/Rituxan (rituximab) plus chlorambucil.
Roche noted that the treatment with Gazyva/Gazyvaro reduced the risk of death by 24% compared to MabThera/Rituxan-based treatment.
Roche chief medical officer and Global Product Development head Sandra Horning said: “We are very pleased that the majority of patients treated with Gazyva/Gazyvaro are still alive after nearly five years of follow-up in the CLL11 study.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“This meaningful survival benefit compared to MabThera/Rituxan-based therapy reinforces that Gazyva/Gazyvaro-based therapy is an important option for people with previously untreated CLL.”
The final analysis of the CLL11 study demonstrated a reduction in the risk of disease progression or death of 51% for patients treated with Gazyva/Gazyvaro plus chlorambucil, clinically meaningful improvement in OS for patients receiving the combination and a prolonged time to initiation of the next therapy.
Patients also achieved a higher rate of minimal residual disease negativity versus those treated with MabThera/Rituxan plus chlorambucil.
At present, Gazyva/Gazyvaro is approved in more than 90 countries in combination with chlorambucil for people with previously untreated CLL, based on previously reported data from the CLL11 study.
